In the BioHarmony Drug Report Database

"Preview" Icon

Naxitamab

Danyelza (naxitamab) is an antibody pharmaceutical. Naxitamab was first approved as Danyelza on 2020-11-25. It is used to treat neuroblastoma in the USA.

 

Trade Name

 

Danyelza
 

Common Name

 

naxitamab
 

ChEMBL ID

 

CHEMBL4297984
 

Indication

 

neuroblastoma
 

Drug Class

 

Monoclonal antibodies: tumors

Image (chem structure or protein)

Naxitamab structure rendering